Keep taking telmisartan as you have been told by your doctor or other health care provider, even if you feel well. This website also contains material copyrighted by 3rd parties.
Use telmisartan as ordered by your doctor. These medications may interact and cause very harmful effects. Controlled studies in pregnant women show no evidence of fetal risk.Angiotensin II receptor blocker; inhibits vasoconstrictor and aldosterone-secreting effects of angiotensin IIStore at 25ºC (77ºF); excursions permitted to 15-30ºC (59-86ºF)Tablets should not be removed from blisters until immediately before administrationAdding plans allows you to compare formulary status to other drugs in the same class.To view formulary information first create a list of plans.
40 mg/day PO initially; titrated to 20-80 mg/day PO, depending on response; patients with volume depletion should receive the lower dosage initially, under close supervisionMost of the antihypertensive effect is apparent within 2 weeks and maximal reduction is generally attained after 4 weeksWhen additional blood pressure reduction is required after the 80-mg dose, a diuretic may be addedIndicated for cardiovascular (CV) risk reduction in patients unable to take ACE inhibitorsUnknown whether doses lower than 80 mg are effective in reducing the risk of cardiovascular morbidity and mortalityRenal impairment: No dosage adjustment necessary; hemodialysis (HD) patients at risk for orthostatic hypotensionUse of telmisartan with an ACE inhibitor is not recommendedAutonomic nervous system: Impotence, increased sweating, flushingCardiovascular: Palpitations, dependent edema, angina pectoris, tachycardia, leg edema, abnormal ECGCentral nervous system: Insomnia, somnolence, migraine, vertigo, paresthesia, involuntary muscle contractions, hypoesthesiaGastrointestinal: Flatulence, constipation, gastritis, vomiting, dry mouth, hemorrhoids, gastroenteritis, enteritis, gastroesophageal reflux, toothache, nonspecific gastrointestinal disordersMetabolic: Gout, hypercholesterolemia, diabetes mellitusResistance mechanism: Infection, fungal infection, abscess, otitis mediaRespiratory: Asthma, bronchitis, rhinitis, dyspnea, epistaxisSkin: Dermatitis, rash, eczema, pruritus; Urinary: micturition frequency, cystitis; Special senses: Abnormal vision, conjunctivitis, tinnitus, earacheMost frequent spontaneously reported events include: headache, dizziness, asthenia, coughing, nausea, fatigue, weakness, edema, face edema, lower limb edema, angioneurotic edema, urticaria, hypersensitivity, sweating increased, erythema, chest pain, atrial fibrillation, congestive heart failure, myocardial infarction, blood pressure increased, hypertension aggravated, hypotension (including postural hypotension), hyperkalemia, syncope, dyspepsia, diarrhea, pain, urinary tract infection, erectile dysfunction, back pain, abdominal pain, muscle cramps (including leg cramps), myalgia, bradycardia, eosinophilia, thrombocytopenia, uric acid increased, abnormal hepatic function/liver disorder, renal impairment including acute renal failure, anemia, increased CPK, anaphylactic reaction, tendon pain (including tendonitis, tenosynovitis), drug eruption (toxic skin eruption mostly reported as toxicoderma, rash, and urticaria), hypoglycemia (in diabetic patients), and angioedema (with fatal outcome)Hypersensitivity to telmisartan or any other component of this product Coadministration with aliskiren in patients with diabetesUse of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and deathHyperkalemia may occur in patients on ARBs, particularly in patients with advanced renal impairment, heart failure, on renal replacement therapy, or on potassium supplements, potassium-sparing diuretics, potassium-containing salt substitutes or other drugs that increase potassium levelAs the majority of telmisartan is eliminated by biliary excretion, patients with biliary obstructive disorders or hepatic insufficiency can be expected to have reduce clearancePregnancy (2nd and 3rd trimesters); significant risk of fetal or neonatal morbidity and mortality (see Black Box Warnings)Dual blockade of the renin-angiotensin system with angiotensin-receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, or aliskiren is associated with increased risk of hypotension, hyperkalemia, and altered renal function (including acute renal failure) in comparison with monotherapyMost patients receiving the combination of two RAS inhibitors do not obtain any additional benefit compared to monotherapy; avoid combined use of RAS inhibitors; closely monitor blood pressure, renal function and electrolytes in patients on benazepril and other agents that affect the RASMay cause fetal harm when administered to a pregnant womanUse of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and deathMost epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agentsWhen pregnancy is detected, discontinue as soon as possibleThere is no information regarding the presence of telmisartan in human milk, the effects on the breastfed infant, or the effects on milk productionAdvise a nursing woman not to breastfeed during treatmentA: Generally acceptable.
Follow all instructions closely. 2002
https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9yZWZlcmVuY2UubWVkc2NhcGUuY29tL2RydWcvbWljYXJkaXMtdGVsbWlzYXJ0YW4tMzQyMzIy
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
It is also safe for long-term use.
Read all information given to you.
This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.Things to remember when you fill your prescription.WebMD does not provide medical advice, diagnosis or treatment.
Diseases & Conditions
and formulary information changes.
If you log out, you will be required to enter your username and password the next time you visit.
Consult your healthcare professional (e.g., doctor or pharmacist) for more in formation.Selected from data included with permission and copyrighted by First Databank, Inc. Onset: 1-2 hours. 2001
Contraindications. Please confirm that you would like to log out of Medscape. /viewarticle/937371